+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Atopic Dermatitis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

  • ID: 4911355
  • Report
  • October 2019
  • Region: Global
  • 145 pages
  • Transparency Market Research
1 of 3

FEATURED COMPANIES

  • LEO Pharma A/S
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
  • MORE
Atopic Dermatitis Drugs Market: Scope of the Study

A new study on the global atopic dermatitis drugs market was published. It presents a wealth of information on key market dynamics, including the drivers, market trends, and challenges, as well as the structure of the atopic dermatitis drugs market. The study offers valuable information about the atopic dermatitis drugs market, to illustrate how the market is expected to expand during the forecast period of 2019-2027.

Key indicators of market growth, which include value chain as well as supply chain analysis, and compound annual growth rate (CAGR), are elucidated in The study in a comprehensive manner. This data can help readers interpret the quantitative growth aspects of the atopic dermatitis drugs market for the forecast period.

An extensive analysis on leading market players’ business strategies is also featured in The study on the atopic dermatitis drugs market. This can help readers understand the principal factors to foresee growth in the atopic dermatitis drugs market. In this study, readers can also find specific data on the qualitative and quantitative growth avenues for the atopic dermatitis drugs market, which is expected to guide market players in making apt decisions in the future.

Key Questions Answered in the Atopic Dermatitis Drugs Market Study
  • What is the scope of growth of atopic dermatitis drug companies in the pharmaceutical drugs sector?
  • What is the estimated Y-o-Y growth of the atopic dermatitis drugs market from 2019 to 2027?
  • What is the influence of the changing trends in technologies on the atopic dermatitis drugs market?
  • Is North America likely to continue to remain the most profitable regional market for atopic dermatitis drug providers?
  • Which factors are expected to hamper the atopic dermatitis drugs market during the forecast period?
  • Which are the leading companies in the global atopic dermatitis drugs market?
Research Methodology

A unique research methodology is utilized to conduct comprehensive research on the growth of the atopic dermatitis drugs market, and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary resources referred to by analysts during the production of the atopic dermatitis drugs market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of The study on the atopic dermatitis drugs market, as a primary resource.

These primary and secondary resources provided exclusive information during the interviews, which serves as a validation from the atopic dermatitis drugs market industry leaders. Access to an extensive internal repository and external proprietary databases allows for this report to address specific details and questions about the atopic dermatitis drugs market with accuracy. The study also uses a top-down approach to assess the numbers for each segment, and a bottom-up approach to counter-validate them. This has helped in making estimates on the future prospects of the atopic dermatitis drugs market more reliable and accurate.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • LEO Pharma A/S
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi
  • MORE
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Atopic Dermatitis Drugs Market

4. Market Overview
4.1. Introduction
4.1.1. Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, 2017–2027

5. Market Outlook
5.1. Disease Epidemiology
5.2. Pipeline Analysis
5.3. Recent Development

6. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Drug Class
6.1. Introduction & Definition
6.2. Market Value Forecast by Drug Class, 2017–2027
6.2.1. Corticosteroids
6.2.2. PDE4 Inhibitors
6.2.3. Biologics
6.2.4. Skin Barrier Emollients
6.2.5. CNI Immunosuppressants
6.2.6. Others
6.3. Market Attractiveness by Drug Class

7. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Distribution Channel
7.1. Introduction & Definition
7.2. Market Value Forecast by Distribution Channel, 2017–2027
7.2.1. Hospital Pharmacies
7.2.2. Retail Pharmacies
7.2.3. Online Pharmacies
7.3. Market Attractiveness by Distribution Channel

8. Global Atopic Dermatitis Drugs Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness by Country/Region

9. North America Atopic Dermatitis Drugs Market Analysis and Forecast
9.1. Introduction
9.2. Market Value Forecast by Drug Class, 2017–2027
9.2.1. Corticosteroids
9.2.2. PDE4 Inhibitors
9.2.3. Biologics
9.2.4. Skin Barrier Emollients
9.2.5. CNI Immunosuppressants
9.2.6. Others
9.3. Market Value Forecast by Distribution Channel, 2017–2027
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Market Value Forecast by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Drug Class
9.5.2. By Distribution Channel
9.5.3. By Country

10. Europe Atopic Dermatitis Drugs Market Analysis and Forecast
10.1. Introduction
10.2. Market Value Forecast by Drug Class, 2017–2027
10.2.1. Corticosteroids
10.2.2. PDE4 Inhibitors
10.2.3. Biologics
10.2.4. Skin Barrier Emollients
10.2.5. CNI Immunosuppressants
10.2.6. Others
10.3. Market Value Forecast by Distribution Channel, 2017–2027
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Market Value Forecast by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Drug Class
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region

11. Asia Pacific Atopic Dermatitis Drugs Market Analysis and Forecast
11.1. Introduction
11.2. Market Value Forecast by Drug Class, 2017–2027
11.2.1. Corticosteroids
11.2.2. PDE4 Inhibitors
11.2.3. Biologics
11.2.4. Skin Barrier Emollients
11.2.5. CNI Immunosuppressants
11.2.6. Others
11.3. Market Value Forecast by Distribution Channel, 2017–2027
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Market Value Forecast by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Drug Class
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region

12. Latin America Atopic Dermatitis Drugs Market Analysis and Forecast
12.1. Introduction
12.2. Market Value Forecast by Drug Class, 2017–2027
12.2.1. Corticosteroids
12.2.2. PDE4 Inhibitors
12.2.3. Biologics
12.2.4. Skin Barrier Emollients
12.2.5. CNI Immunosuppressants
12.2.6. Others
12.3. Market Value Forecast by Distribution Channel, 2017–2027
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Market Value Forecast by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Drug Class
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region

13. Middle East & Africa Atopic Dermatitis Drugs Market Analysis and Forecast
13.1. Introduction
13.2. Market Value Forecast by Drug Class, 2017–2027
13.2.1. Corticosteroids
13.2.2. PDE4 Inhibitors
13.2.3. Biologics
13.2.4. Skin Barrier Emollients
13.2.5. CNI Immunosuppressants
13.2.6. Others
13.3. Market Value Forecast by Distribution Channel, 2017–2027
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Market Value Forecast by Country/Sub-region, 2017–2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Drug Class
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region

14. Competitive Landscape
14.1. Company Profiles
14.1.1. Mylan N.V.
14.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.1.2. Product Portfolio
14.1.1.3. SWOT Analysis
14.1.1.4. Strategic Overview
14.1.1.5. Financial Overview
14.1.2. Pfizer, Inc.
14.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.2.2. Product Portfolio
14.1.2.3. SWOT Analysis
14.1.2.4. Strategic Overview
14.1.2.5. Financial Overview
14.1.3. LEO Pharma A/S
14.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.3.2. Product Portfolio
14.1.3.3. SWOT Analysis
14.1.3.4. Strategic Overview
14.1.3.5. Financial Overview
14.1.4. Teva Pharmaceutical Industries Ltd
14.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.4.2. Product Portfolio
14.1.4.3. SWOT Analysis
14.1.4.4. Strategic Overview
14.1.4.5. Financial Overview
14.1.5. Sanofi
14.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.5.2. Product Portfolio
14.1.5.3. SWOT Analysis
14.1.5.4. Strategic Overview
14.1.5.5. Financial Overview
14.1.6. Novartis AG
14.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.1.6.2. Product Portfolio
14.1.6.3. SWOT Analysis
14.1.6.4. Strategic Overview
14.1.6.5. Financial Overview
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Mylan N.V.
  • Pfizer, Inc.
  • LEO Pharma A/S
  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • Novartis AG
Note: Product cover images may vary from those shown
Adroll
adroll